RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2023 -- Pappas Capital, a leading investor in next-generation life science and technology companies, announced today that Nick Pappas (no relation) has joined the firm as...
BioSyntech specialized in the development, manufacturing and commercialization of biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The company’s assets were acquired in 2010 by Piramal Healthcare Ltd.
BioSyntech
Laval, Quebec
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.